91 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
6
Identification, Synthesis, and Biological Evaluation of the Major Human Metabolite of NLRP3 Inflammasome Inhibitor MCC950.
The University of Queensland
6
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
Smith, Gambrell & Russell
5
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.
Smith, Gambrell & Russell
31
Discovery of Potent and Brain-Penetrant Bicyclic NLRP3 Inhibitors with Peripheral and Central In Vivo Activity.
A Johnson & Johnson Company
5
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
Smith, Gambrell & Russell
39
Discovery, synthesis, and biological mechanism evaluation of novel quinoline derivatives as potent NLRP3 inhibitors.
Guangzhou Medical University
12
Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors.
Ocean University of China
5
Scaffold hopping-driven optimization for the identification of NLRP3 inhibitors as potential gout therapeutics.
Peking University
22
Deep-Learning-Driven Discovery of SN3-1, a Potent NLRP3 Inhibitor with Therapeutic Potential for Inflammatory Diseases.
Peking University
22
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.
IFM Therapeutics GmbH
41
Design, synthesis, and pharmacological characterization of sulfonylurea-based NLRP3 inhibitors: Towards an effective therapeutic strategy for Alzheimer's disease.
Peking University
3
Design, synthesis and biological evaluation of sulfonylurea derivatives as NLRP3 inflammasome inhibitors.
East China University of Science and Technology
17
Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome.
Novartis Biomedical Research
20
Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment.
Cerevance Limited
4
Discovery of NLRP3 inhibitors using machine learning: Identification of a hit compound to treat NLRP3 activation-driven diseases.
Peking University
10
Small molecule inhibitors of NLRP3 inflammasome and GSK-3β in the management of traumatic brain injury: A review.
National Institute of Pharmaceutical Education and Research (NIPER)
13
Design, synthesis and biological evaluation of tanshinone IIA derivatives as NLRP3 inflammasome inhibitors.
Guangzhou Medical University
6
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.
Smith, Gambrell & Russell
2
Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis.
Sichuan University
55
Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen.
Fudan University
6
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
Smith, Gambrell & Russell
1
Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD Immunotherapy.
Fudan University
27
The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening.
BioAge Labs
9
Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer's disease.
Chonnam National University
10
Total synthesis/semi-synthesis of natural isopentenyl flavonoids with inhibitory activity on NLRP3 inflammasome.
East China University of Science and Technology
35
Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
Sichuan University
21
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.
Novartis Biomedical Research
26
Design and Discovery of Novel NLRP3 Inhibitors and PET Imaging Radiotracers Based on a 1,2,3-Triazole-Bearing Scaffold.
Virginia Commonwealth University
20
Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023.
Shenyang Pharmaceutical University
8
Identification and Validation of PKR as a Direct Target for the Novel Sulfonamide-Substituted Tetrahydroquinoline Nonselective Inhibitor of the NLRP3 Inflammasome.
China Pharmaceutical University
33
Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity.
China Pharmaceutical University
13
Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis.
China Pharmaceutical University
112
Recent Progress and Prospects of Small Molecules for NLRP3 Inflammasome Inhibition.
Sichuan University
22
Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice.
AstraZeneca
4
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer.
University of Ferrara
1
Scaffold Hybrid of the Natural Product Tanshinone I with Piperidine for the Discovery of a Potent NLRP3 Inflammasome Inhibitor.
Zhejiang University
36
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders.
Nodthera
42
Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis.
Sichuan University
32
Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis.
Ocean University of China
6
Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease.
Smith, Gambrell & Russell
6
Fused Bicyclic Heteroaryl Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
Smith, Gambrell & Russell
21
Discovery of a dual-acting inhibitor of interleukin-1β and STATs for the treatment of inflammatory bowel disease.
Guangzhou Medical University
32
Discovery of Novel NLRP3 Inflammasome Inhibitors Composed of an Oxazole Scaffold Bearing an Acylsulfamide.
Japan Tobacco
8
Advancements in Predictive Medicine: NLRP3 Inflammasome Inhibitors and AI-Driven Predictive Health Analytics.
Usona Institute
2
Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation.
University of Turin
6
1,2,4-Triazine Derivatives as NLRP3 Inhibitors for Treating Diseases.
Smith, Gambrell & Russell
10
Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis.
School of Pharmacy Anhui Medical University
46
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors.
Nodthera
29
Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies.
Virginia Commonwealth University
67
Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis.
Sichuan University
2
Callintegers A and B, Unusual Tricyclo[4.4.0.0
Yunnan Research & Development Center For Natural Products
14
Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probes.
Shanghaitech University
31
Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity.
Guangzhou Medical University
10
Design, synthesis, and biological evaluation of oridonin derivatives as novel NLRP3 inflammasome inhibitors for the treatment of acute lung injury.
Nanjing University of Chinese Medicine
8
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress.
Guizhou Medical University
25
Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors.
Roche Innovation Center Shanghai
14
Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis.
Anhui Medical University
45
Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities.
Guangzhou Medical University
38
Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity.
Guangzhou Medical University
1
MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice.
Zhejiang Chinese Medical University
7
Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis.
China Pharmaceutical University
7
Synthesis and biological evaluation of parthenolide derivatives with reduced toxicity as potential inhibitors of the NLRP3 inflammasome.
Guangzhou Medical University
2
Flavonoids with Inhibitory Effects on NLRP3 Inflammasome Activation from
Sichuan University
26
Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.
Cadila Healthcare
2
Dehydrohispanolone Derivatives Attenuate the Inflammatory Response through the Modulation of Inflammasome Activation.
Universidad Complutense De Madrid (Ucm)
21
Discovery and optimization of 4-oxo-2-thioxo-thiazolidinones as NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inhibitors.
Xiamen University
20
Development of novel NLRP3-XOD dual inhibitors for the treatment of gout.
Soochow University
28
Discovery of Second-Generation NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
TBA
18
Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.
Shandong University
29
Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
TBA
25
Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout.
Soochow University
5
Synthesis of deuterium-labelled analogues of NLRP3 inflammasome inhibitor MCC950.
The University of Queensland
10
Synthesis of 1,5-Anhydro-d-fructose derivatives and evaluation of their inflammasome inhibitors.
The Noguchi Institute
29
Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use
Shanghai Ringene Biopharma
5
NOVEL COMPOUND EXHIBITING THERAPEUTIC EFFECT ON INFLAMMATORY DISEASE AS P38 MAP KINASE INHIBITOR
Prazertherapeutics
25
3-TETRAZOLYLMETHYL-1,3,5-TRIAZIN-2,4-DIONE COMPOUND INHIBITING CORONAVIRUS 3CL PROTEASE ACTIVITY AND PREPARATION METHOD AND USE THEREOF
Shaanxi Panlong Pharmaceutical Co.
4
Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.
Fujisawa Pharmaceutical
22
Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors.
Fujisawa Pharmaceutical